Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Runbo ZHONG"'
Publikováno v:
Cancer Biology & Therapy, Vol 25, Iss 1 (2024)
Background To investigate the influence of pretreatment neutrophil-to-lymphocyte ratio (NLR) and procalcitonin (PCT) on progression-free survival (PFS) in extensive-stage small-cell lung cancer (SCLC) patients.Method A total of 100 extensive-stage SC
Externí odkaz:
https://doaj.org/article/f3a06a72f2b0482e968a27edbe10359e
Autor:
Hongyu Liu, Chao Zhou, Haohua Jiang, Tianqing Chu, Runbo Zhong, Xueyan Zhang, Yinchen Shen, Baohui Han
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundChemotherapy combined with PD-1 inhibitor treatment has revolutionized the standard of care for patients with NSCLC. However, the benefit is not universal, highlighting the need for precise prediction factors. Given their relationship with
Externí odkaz:
https://doaj.org/article/acb93639fc344a28be27933120519743
Autor:
Bo Zhang, Hongyu Liu, Chunlei Shi, Zhiqiang Gao, Runbo Zhong, Aiqin Gu, Tianqing Chu, Huimin Wang, Liwen Xiong, Wei Zhang, Xueyan Zhang, Bo Yan, Jiajun Teng, Weimin Wang, Hao Bai, Rong Qiao, Lei Cheng, Yanbin Kuang, Ruiying Zhao, Hua Zhong, Baohui Han
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Resistance to immune checkpoint inhibitors (ICIs) represents a major unmet medical need in non-small cell lung cancer (NSCLC) patients. Vascular endothelial growth factor (VEGF) inhibition may reverse a suppressive microenvironmen
Externí odkaz:
https://doaj.org/article/fd0c3fa6cd7f420a97190e5951f015d2
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background There is inconclusive evidence to suggest that the expression of programmed cell death ligand 1 (PD-L1) is a putative predictor of response to EGFR-TKI therapy in advanced EGFR-mutant non-small cell lung cancer (NSCLC). We evaluat
Externí odkaz:
https://doaj.org/article/c03f36fead7d4b4396e056a6740768cd
Autor:
Liang Zheng, Fang Hu, Wei Nie, Jun Lu, Bo Zhang, Jianlin Xu, Shuyuan Wang, Ying Li, Xiaoxuan Zheng, Wei Zhang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Baohui Han, Hua Zhong, Xueyan Zhang
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Background The 9th edition of the TNM Classification for lung cancer delineates M1c into two subcategories: M1c1 (Multiple extrathoracic lesions within a single organ system) and M1c2 (Multiple extrathoracic lesions involving multiple organ
Externí odkaz:
https://doaj.org/article/5c7af439f5194ea8b098e0278cb05b37
Autor:
Jun Lu, Ying Li, Wei Zhang, Hua Zhong, Fang Hu, Liang Zheng, Xiaohua Yang, Lin Huang, Xueyan Zhang, Tianqing Chu, Baohui Han, Yinchen Shen, Wei Nie, Jianlin Xu, Shuyuan Wang, Runbo Zhong, Xiaoxuan Zheng
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Background Combining immune checkpoint inhibitors (ICIs) with chemotherapy has become a standard treatment for patients with non-small cell lung cancer (NSCLC) lacking driver gene mutations. Reliable biomarkers are essential for predicting treatment
Externí odkaz:
https://doaj.org/article/b9a445ffb44c4e5997bab417d9a49d00
Autor:
Bo Zhang, Hua Zhong, Chunlei Shi, Zhiqiang Gao, Runbo Zhong, Aiqin Gu, Weimin Wang, Tianqing Chu, Liwen Xiong, Wei Zhang, Huimin Wang, Xueyan Zhang, Baohui Han
Publikováno v:
The Clinical Respiratory Journal, Vol 17, Iss 12, Pp 1361-1367 (2023)
Abstract Introduction Durvalumab is a check‐point inhibitor against programmed death ligand‐1 (PD‐L1), and anlotinib is a new orally administered multitarget tyrosine kinase inhibitor (TKI). Both agents have been approved in China. Preclinical
Externí odkaz:
https://doaj.org/article/a5f8528abb824329a4d37c54d296c13e
Publikováno v:
Cancer Medicine, Vol 12, Iss 5, Pp 5372-5383 (2023)
Abstract Objectives Treatments for advanced small‐cell lung cancer (SCLC) patients who are resistant to first‐line chemotherapy are limited. Given that antiangiogenic agents and immune‐checkpoint inhibitors (ICIs) can confer synergistic therape
Externí odkaz:
https://doaj.org/article/4bf96b63d6a94f01829a8fc162b8550b
Publikováno v:
Translational Oncology, Vol 33, Iss , Pp 101671- (2023)
Background: Immune checkpoint blockade (ICB) has been proved to have significant anti-tumor effect in the clinical treatment of non-small cell lung cancer (NSCLC). Therefore, biomarkers predicting ICB response can provide better treatment for patient
Externí odkaz:
https://doaj.org/article/4f6db1b1dd4046709b7a35b0b9192177
Autor:
Tianqing Chu, Jie Yuan, Jun Lu, Wei Nie, Runbo Zhong, Bo Zhang, Wei Zhang, Chunlei Shi, Jialin Qian, Yanwei Zhang, Xueyan Zhang, Jiajun Teng, Zhiqiang Gao, Yuqing Lou, Jiaqi Li, Huiping Qiang, Chao Zhang, Jin Li, Xuefeng Xia, Hua Zhong, Baohui Han
Publikováno v:
Clinical and Translational Medicine, Vol 13, Iss 6, Pp n/a-n/a (2023)
Externí odkaz:
https://doaj.org/article/fd9ef6b280284f8e8036000f7f80b6f9